Macdonald R R, Thorogood J, Mason M K
Department of Obstetrics and Gynaecology, General Infirmary, Belmont Grove, Leeds.
Br J Obstet Gynaecol. 1988 Feb;95(2):166-74.
A randomized trial was arranged in Yorkshire to assess whether progestogens would improve survival as part of the primary treatment of endometrial carcinoma, in conjunction with surgery and radiotherapy. A total of 429 patients was randomized on diagnosis to the progestogen or control group and treated locally according to an agreed protocol. All the patients are now more than 1 year after operation and over half are more than 5 years after operation. The projected overall 5-year survival rate is 76% but contrary to expectation there is no statistically significant difference in survival between the patients treated with progestogens and the control group even after statistical adjustment for known prognostic factors.
在约克郡进行了一项随机试验，以评估孕激素作为子宫内膜癌主要治疗方法的一部分，与手术和放疗联合使用时是否能提高生存率。共有429例患者在确诊时被随机分为孕激素组或对照组，并根据商定的方案进行局部治疗。所有患者目前均已术后1年以上，半数以上患者已术后5年以上。预计总体5年生存率为76%，但与预期相反，即使在对已知预后因素进行统计调整后，接受孕激素治疗的患者与对照组之间的生存率在统计学上也没有显著差异。
